SEC Company Response from TuHURA Biosciences, (HURA) — Jul 11, 2019
TuHURA Biosciences, Inc./NV (HURA) (CIK 0001498382)
Date: July 11, 2019 · CIK: 0001498382 · Accession: 0001213900-19-012526
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-232332
Letter
DelMar Pharmaceuticals, Inc.
Suite 720-999 West Broadway
Vancouver, British Columbia, Canada V5Z 1K5
July 11, 2019
VIA EDGAR SUBMISSION
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, NE
Washington, D.C. 20549
Re: REQUEST FOR ACCELERATION OF EFFECTIVENESS
DelMar Pharmaceuticals, Inc.
Registration Statement on Form S-1, as amended
File No. 333-232332
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, we hereby request acceleration of the effective date of the above-referenced registration statement to Tuesday, July 16, 2019, at 5:00 p.m., Eastern Time, or as soon thereafter as is practicable.
Once the registration statement has been declared effective, please orally confirm that event with Sarah Cole of Lowenstein Sandler LLP at (646) 414-6958.
Very truly yours,
DelMar Pharmaceuticals, Inc.
Show Raw Text
CORRESP
1
filename1.htm
DelMar Pharmaceuticals, Inc.
Suite 720-999 West Broadway
Vancouver, British Columbia, Canada V5Z
1K5
July 11, 2019
VIA EDGAR SUBMISSION
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, NE
Washington, D.C. 20549
Re:
REQUEST FOR ACCELERATION OF EFFECTIVENESS
DelMar Pharmaceuticals, Inc.
Registration Statement on Form S-1, as amended
File No. 333-232332
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended,
we hereby request acceleration of the effective date of the above-referenced registration statement to Tuesday, July 16,
2019, at 5:00 p.m., Eastern Time, or as soon thereafter as is practicable.
Once the registration statement has been
declared effective, please orally confirm that event with Sarah Cole of Lowenstein Sandler LLP at (646) 414-6958.
Very truly yours,
DelMar Pharmaceuticals, Inc.
By:
/s/ Saiid Zarrabian
Name:
Saiid Zarrabian
Title:
Chief Executive Officer